Condition
Ovarian Cancer Metastatic
Total Trials
4
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Recruiting2
Withdrawn1
Active Not Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07444814Phase 1Recruiting
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
NCT07311577Phase 2RecruitingPrimary
Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study
NCT07009743Active Not Recruiting
O-RADS MRI System on Early Detection of Ovarian Cancer
NCT04389229Phase 1WithdrawnPrimary
OVSTAR TIL Trial (OVarian Cancer Co-STimulatory Antigen Receptor TIL Trial)
Showing all 4 trials